Herman Steen, Chief Executive Officer, Co-founder
Herman Steen holds a PhD in pharmacology from the University of Groningen in 1992. He worked at Byk Gulden (Altana Pharma/Nycomed/Takeda) and in 1998 he founded PharmaScope, a clinical contract research and pharma recruitment organization. After selling PharmaScope to Quintiles Transnational Corp., the international operating Orphan drug CRO PSR Group was established and sold to Ergomed plc. Dr. Steen has extensive experience in clinical research and as a pharma-biotech serial-entrepreneur he is heavily involved in commercialization and bridging the pre-clinical research into the clinic.
Guus van Scharrenburg, Chief Operations Officer
Guus van Scharrenburg obtained his PhD (cum laude) at the University of Utrecht on the structure-function relationship of lipolytic enzymes. He has over more than 30 years of experience in the pharmaceutical industry (Solvay, Abbott) with responsibility for programs and projects in all R&D phases. During his career he was responsible for R&D alliances with big Pharma partners as well as smaller innovative biotechs. He was Head of Biotechnology of Solvay in Weesp (NL) and Global Project Director of the Solvay -Bristol-Myers Squibb alliance for development of CB1 antagonists. In addition, he was involved in neurology research programs, responsible for phase II and III development projects for cardio-metabolic and neurology indications, respectively.
Paul van Meurs, Chief Business Officer
Paul van Meurs received his MD degree from the Erasmus University of Rotterdam in 1989. He worked at AstraZeneca and TEVA in clinical research and medical affairs positions in the neurological and cardiovascular area. He managed a Site Management Organization from 2001 to 2007 and subsequently worked in commercial roles in the Medical Imaging field for over 10 years for Bioclinica and Keosys. Dr van Meurs has extensive experience in commercial support of clinical development services organizations.